This is a summary of the European public assessment report (EPAR) for Duloxetine Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duloxetine Mylan. For practical information about using Duloxetine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
* Treatment of major depressive disorder * Treatment of diabetic peripheral neuropathic pain * Treatment of generalised anxiety disorder * Duloxetine Viatris is indicated in adults
Therapeutic Area (MeSH)
ATC Code
N06AX21
ATC Item
N/A
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| duloxetine | N/A | duloxetine |
EMA Name
Duloxetine Viatris (previously Duloxetine Mylan)
Medicine Name
Duloxetine Viatris (previously Duloxetine Mylan)
Aliases
N/ANo risk management plan link.
